SavedAdd your journal

Journals / Journal of Basic and Clinical Health Sciences / 2021 / Cilt: 5 - Sayı: 1

DRUG RESISTANCE MECHANISMS ON COLORECTAL CANCER

Ezgi DAŞKIN
Hülya ELLİDOKUZ
Hasan KURTER
Janberk YEŞİL
Gizem ÇALIBAŞI KOCAL
Yasemin BAŞBİNAR
Pages
88–93
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, current drug resistance mechanisms were discussed and then mechanisms of conventional chemotherapy related resistance were explained.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Standard treatment for colorectal cancer includes surgery, radiotherapy, and chemotherapy.
📊
Key Findings & Data:Conventional chemotherapeutic agents used in colorectal cancer such as 5-fluorouracil, capecitabine which is oral form of 5-fluorouracil, irinotecan, and oxaliplatin.
💡
Conclusion & Impact:In this review, current drug resistance mechanisms were discussed and then mechanisms of conventional chemotherapy related resistance were explained.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Standard treatment for colorectal cancer includes surgery, radiotherapy, and chemotherapy. Conventional chemotherapeutic agents used in colorectal cancer such as 5-fluorouracil, capecitabine which is oral form of 5-fluorouracil, irinotecan, and oxaliplatin. One of the major challenges in chemotherapy considered as drug resistance. Drug resistance occurs in many different mechanisms such as alteration in tumor microenvironment, growth kinetics, genetic variations, and tumor heterogeneity. These cytotoxic agents are used in combination form to overcome drug resistance on colorectal cancer. They can also be used in combination with cytotoxic agents as bevacizumab and cetuximab. Combination therapy depends on tumor burden, type, stage, and molecular characteristics. It is crucial to choose the combination therapy to be applied by taking these factors into consideration. In this review, current drug resistance mechanisms were discussed and then mechanisms of conventional chemotherapy related resistance were explained.

🔖

Cite This Article

DAŞKIN, E., ELLİDOKUZ, H., KURTER, H., YEŞİL, J., KOCAL, G. Ç., BAŞBİNAR, Y. (2022). DRUG RESISTANCE MECHANISMS ON COLORECTAL CANCER. Journal of Basic and Clinical Health Sciences, Cilt: 5 - Sayı: 1, 88–93. https://ajindex.com/articles/560535

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (18)

  1. Longley DB, Allen WL, Johnston PG. Drug resistance, predictive markers and pharmacogenomics in colorectal cancer. Biochim Biophys Acta. 2006; 1766(2):184-196
  2. Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet. 2019; 394(10207):1467-1480
  3. Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019; 575(7782):299-309
  4. Wang X, Zhang H, Chen X. Drug resistance and combating drug resistance in cancer. Cancer Drug Resist 2019; 2:141-160
  5. Goldie, J. H. & Coldman, A. J. The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res 1984; 44:3643–3653
  6. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 1979;63(11-12):1727-1733
  7. Norton, L., Simon, R., Brereton, H. D. & Bogden, A. E. Predicting the course of Gompertzian growth. Nature 1976; 264:542– 545
  8. Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018; 15(2):81– 94
  9. Sutherland KD, Visvader JE. Cellular Mechanisms Underlying Intertumoral Heterogeneity. Trends Cancer. 2015; 1(1):15- 23
  10. Hinohara K, Polyak K. Intratumoral Heterogeneity: More Than Just Mutations. Trends Cell Biol. 2019; 29(7):569-579
  11. Gausachs M, Borras E, Chang K, et al. Mutational Heterogeneity in APC and KRAS Arises at the Crypt Level and Leads to Polyclonality in Early Colorectal Tumorigenesis. Clin Cancer Res. 2017; 23(19):5936–5947
  12. Sun Y. Tumor microenvironment and cancer therapy resistance. Cancer Lett. 2016; 380(1):205–215
  13. Haider T, Pandey V, Banjare N, Gupta PN, Soni V. Drug resistance in cancer: mechanisms and tackling strategies. Pharmacol Rep. 2020; 72(5):1125-1151
  14. Deng J, Wang Y, Lei J, Lei W, Xiong JP. Insights into the involvement of noncoding RNAs in 5-fluorouracil drug resistance. Tumour Biol. 2017; 39(4):1010428317697553
  15. Longley DB, Harkin DP, Johnston PG. 5- fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003; 3(5):330- 338
  16. Cao X, Hou J, An Q, Assaraf YG, Wang X. Towards the overcoming of anticancer drug resistance mediated by p53 mutations. Drug Resist Updat. 2020; 49:100671
  17. Blondy S, David V, Verdier M, Mathonnet M, Perraud A, Christou N. 5-Fluorouracil resistance mechanisms in colorectal cancer: From classical pathways to promising processes. Cancer Sci. 2020; 111(9):3142- 3154
  18. Fujii R, Seshimo A, Kameoka